These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31066966)

  • 1. Plasma-free amino acid profiles in dogs with hepatocellular carcinoma.
    Leela-Arporn R; Ohta H; Tamura M; Nagata N; Sasaoka K; Dermlim A; Nisa K; Osuga T; Morishita K; Sasaki N; Takiguchi M
    J Vet Intern Med; 2019 Jul; 33(4):1653-1659. PubMed ID: 31066966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma free amino acid profiling of esophageal cancer using high-performance liquid chromatography spectroscopy.
    Ma H; Hasim A; Mamtimin B; Kong B; Zhang HP; Sheyhidin I
    World J Gastroenterol; 2014 Jul; 20(26):8653-9. PubMed ID: 25024622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
    Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W
    Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum metabolites may be useful markers to assess vascular invasion and identify normal alpha-fetoprotein in hepatocellular carcinoma undergoing liver resection: a pilot study.
    Lee CW; Yu MC; Lin G; Chiu JC; Chiang MH; Sung CM; Hsieh YC; Kuo T; Lin CY; Tsai HI
    World J Surg Oncol; 2020 Jun; 18(1):121. PubMed ID: 32493393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutathione species and metabolomic prints in subjects with liver disease as biological markers for the detection of hepatocellular carcinoma.
    Sanabria JR; Kombu RS; Zhang GF; Sandlers Y; Ai J; Ibarra RA; Abbas R; Goyal K; Brunengraber H
    HPB (Oxford); 2016 Dec; 18(12):979-990. PubMed ID: 28340971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma amino acid concentrations in dogs with hepatic disease.
    Strombeck DR; Rogers Q
    J Am Vet Med Assoc; 1978 Jul; 173(1):93-6. PubMed ID: 670060
    [No Abstract]   [Full Text] [Related]  

  • 8. Untargeted metabolomics of blood plasma samples of patients with hepatocellular carcinoma.
    Böhmová A; Mikoška M; Syslová K; Šindelářová D; Hříbek P; Urbánek P; Setnička V
    J Pharm Biomed Anal; 2024 Sep; 248():116263. PubMed ID: 38852296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
    Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
    [No Abstract]   [Full Text] [Related]  

  • 10. Perioperative dynamics and significance of amino acid profiles in patients with cancer.
    Gu Y; Chen T; Fu S; Sun X; Wang L; Wang J; Lu Y; Ding S; Ruan G; Teng L; Wang M
    J Transl Med; 2015 Jan; 13():35. PubMed ID: 25622826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma.
    Wen Y; Han J; Chen J; Dong J; Xia Y; Liu J; Jiang Y; Dai J; Lu J; Jin G; Han J; Wei Q; Shen H; Sun B; Hu Z
    Int J Cancer; 2015 Oct; 137(7):1679-90. PubMed ID: 25845839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of aminoaciduria and hypoaminoacidemia in dogs with hepatocutaneous syndrome.
    Loftus JP; Center SA; Lucy JM; Stanton JA; McDonough SP; Peters-Kennedy J; Arceneaux KA; Bechtold MA; Bennett CL; Bradbury CA; Cline MG; Hall-Fonte DL; Hammer-Landrum JF; Huntingford JL; Marshall J; Sharpe KS; Redin JL; Selva ST; Lucia TA
    Am J Vet Res; 2017 Jun; 78(6):735-744. PubMed ID: 28541155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma.
    Stepien M; Lopez-Nogueroles M; Lahoz A; Kühn T; Perlemuter G; Voican C; Ciocan D; Boutron-Ruault MC; Jansen E; Viallon V; Leitzmann M; Tjønneland A; Severi G; Mancini FR; Dong C; Kaaks R; Fortner RT; Bergmann MM; Boeing H; Trichopoulou A; Karakatsani A; Peppa E; Palli D; Krogh V; Tumino R; Sacerdote C; Panico S; Bueno-de-Mesquita HB; Skeie G; Merino S; Ros RZ; Sánchez MJ; Amiano P; Huerta JM; Barricarte A; Sjöberg K; Ohlsson B; Nyström H; Werner M; Perez-Cornago A; Schmidt JA; Freisling H; Scalbert A; Weiderpass E; Christakoudi S; Gunter MJ; Jenab M
    Int J Cancer; 2022 Apr; 150(8):1255-1268. PubMed ID: 34843121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
    Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
    World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma.
    Gao R; Cheng J; Fan C; Shi X; Cao Y; Sun B; Ding H; Hu C; Dong F; Yan X
    Sci Rep; 2015 Dec; 5():18175. PubMed ID: 26658617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma microRNA might as a potential biomarker for hepatocellular carcinoma and chronic liver disease screening.
    Jiang L; Li X; Cheng Q; Zhang BH
    Tumour Biol; 2015 Sep; 36(9):7167-74. PubMed ID: 25894380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
    Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
    Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma.
    Zhang HJ; Yao DF; Yao M; Huang H; Wu W; Yan MJ; Yan XD; Chen J
    World J Gastroenterol; 2012 Nov; 18(41):5897-904. PubMed ID: 23139605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function.
    Okajima W; Komatsu S; Ichikawa D; Miyamae M; Kawaguchi T; Hirajima S; Ohashi T; Imamura T; Kiuchi J; Arita T; Konishi H; Shiozaki A; Moriumura R; Ikoma H; Okamoto K; Taniguchi H; Itoh Y; Otsuji E
    Oncotarget; 2016 Aug; 7(33):53820-53836. PubMed ID: 27462777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of hepatocellular carcinoma in hepatitis C patients: biomarker discovery by LC-MS.
    Bowers J; Hughes E; Skill N; Maluccio M; Raftery D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 966():154-62. PubMed ID: 24666728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.